Tirzepatide studies
4,040 journal papers mention Tirzepatide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.
Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Tirzepatide is safe, effective or approved for any use.
- Papers
- 4,040
- 3,147 articles, 893 reviews
- Earliest paper
- 2017
- Most papers in 2026 (1,675)
- Open access
- 65%
- free to read somewhere
- Reviews
- 22%
- of all papers listed
What kind of studies
Of 2,729 papers in PubMed that mention Tirzepatide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.
- Randomized controlled trials134
- Other clinical trials11
- Meta-analyses and systematic reviews224
- Other reviews998
- Case reports169
- Animal studies only78
- Studies in humans1,479
Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).
Registered clinical studies
Studies on ClinicalTrials.gov that mention Tirzepatide in their intervention details. A registration says a study is planned or running, not what it found.
- Registered
- 310
- Completed
- 92
- Ongoing or planned
- 207
- Phase 1
- 41
- Phase 2
- 80
- Phase 3
- 60
- Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s
NCT07832084Not yet recruitingPhase 4started 2026-12
- A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT07881458Not yet recruitingPhase 3started 2026-11
- A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes
NCT07881432Not yet recruitingPhase 3started 2026-12
- Tirzepatide for Treatment of CCCA
NCT07734870RecruitingPhase 2started 2026-09-15
- Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea
NCT07846865Not yet recruitingPhase 2 / Phase 3started 2026-10-01
The five most recently updated studies. See all 310 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.
Papers per year
2017 to 2026, peak 1,675 papers in a year. The latest year may still be incomplete.
Where it is published
- Diabetes258 papers
- Diabetes Obesity and Metabolism177 papers
- Cureus119 papers
- Journal of the Endocrine Society72 papers
- Endocrine Practice46 papers
The papers
Most citedName in the title
- Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael Albrecht Nauck, David A. D’Alessio · Cardiovascular Diabetology · 2022
ReviewOpen access · CC BY407 citationsRead the open copy →
- The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
Thinzar Min, Stephen Charles Bain · Diabetes Therapy · 2020
ReviewOpen access · CC BY-NC287 citationsRead the open copy →
- Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Thomas Karagiannis, Ioannis Avgerinos, Aris Liakos et al. · Diabetologia · 2022
Meta-analysisOpen access · CC BY273 citationsRead the open copy →
- Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Vivek P. Chavda, Jinal Ajabiya, Divya Teli et al. · Molecules · 2022
ReviewOpen access · CC BY208 citationsRead the open copy →
- Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Ryan J. Jalleh, Mark Philip Plummer, Chinmay S. Marathe et al. · The Journal of Clinical Endocrinology & Metabolism · 2024
ReviewOpen access · CC BY158 citationsRead the open copy →
LatestName in title or abstract
- EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW
Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026
ReviewOpen accessRead the open copy →
- Switching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses
Eyal Schwartzberg, Erez Berman, Segev Shani et al. · Expert Opinion on Pharmacotherapy · 2026
ReviewOpen access · CC BY-NC-NDRead the open copy →
- Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
Jingyi Zhang, 王永健, Jinjin Li et al. · Drugs · 2026
Systematic review
- Interpreting Diabetic Retinal Outcomes After GLP ‐1 Receptor Agonist and Tirzepatide Initiation: Clinical Evidence and Its Limits
Ben Wu, Bin‐Sheng He · Diabetes Obesity and Metabolism · 2026
ReviewOpen accessRead the open copy →
- GLP‐1–Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection
Thales Rossatto, Ricardo de Andrade Oliveira, Andréia Machado Cardoso · Diabetes Obesity and Metabolism · 2026
ReviewOpen access · CC BYRead the open copy →
- Beyond glycemic control: emerging therapeutic applications of GLP-1 receptor agonists: a comprehensive narrative review
Nidhi Srivastava, Siddhant Mehrotra, Shubham Biswas et al. · International Journal of Basic & Clinical Pharmacology · 2026
ReviewOpen access · CC BY-NC-NDRead the open copy →
- Practical Challenges of Switching and Cross-Titration Between Incretin-Based Therapies in Type 2 Diabetes and Obesity: A Narrative Review
Jana Makuc, Miodrag Janić · Journal of Clinical Medicine · 2026
ReviewOpen access · CC BYRead the open copy →
Each list shows up to 40 papers.See all 4,040 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:30 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.